| 1 |
Liu B, Cheng L, Gao H, Zhang J, Dong Y, Gao W, Yuan S, Gong T, Huang W. The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer. Cancer Lett 2023;553:215996. [PMID: 36343787 DOI: 10.1016/j.canlet.2022.215996] [Reference Citation Analysis]
|
| 2 |
Li Y, Wang Q, Li J, Li A, Wang Q, Zhang Q, Chen Y. Therapeutic modulation of V Set and Ig domain-containing 4 (VSIG4) signaling in immune and inflammatory diseases. Cytotherapy 2023:S1465-3249(22)01074-X. [PMID: 36642683 DOI: 10.1016/j.jcyt.2022.12.004] [Reference Citation Analysis]
|
| 3 |
Li X, Liu J, Zhao Y, Xu N, Lv E, Ci C, Li X. 1,25-dihydroxyvitamin D3 ameliorates lupus nephritis through inhibiting the NF-κB and MAPK signalling pathways in MRL/lpr mice. BMC Nephrol 2022;23:243. [PMID: 35804318 DOI: 10.1186/s12882-022-02870-z] [Reference Citation Analysis]
|
| 4 |
Fernandez-Ruiz R, Belmont HM. The role of anticomplement therapy in lupus nephritis. Transl Res 2022;245:1-17. [PMID: 35158097 DOI: 10.1016/j.trsl.2022.02.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Aringer M, Alarcón-riquelme ME, Clowse M, Pons-estel GJ, Vital EM, Dall’era M. A glimpse into the future of systemic lupus erythematosus. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210867. [DOI: 10.1177/1759720x221086719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 6 |
Song J, Zhao R, Yan C, Luo S, Xi J, Ding P, Li L, Hu W, Zhao C. A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation. Front Immunol 2022;13:746068. [PMID: 35154091 DOI: 10.3389/fimmu.2022.746068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Vandendriessche S, Cambier S, Proost P, Marques PE. Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis. Front Cell Dev Biol 2021;9:624025. [PMID: 33644062 DOI: 10.3389/fcell.2021.624025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 8 |
Frangou E, Georgakis S, Bertsias G. Update on the cellular and molecular aspects of lupus nephritis. Clin Immunol 2020;216:108445. [PMID: 32344016 DOI: 10.1016/j.clim.2020.108445] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
